Company | Cap $ | P/E | P/B | P/S | ROE | ROA | ROS | L/A | P/FCF | PR | Period |
---|---|---|---|---|---|---|---|---|---|---|---|
AbbVie | 293,959 | 2023 | |||||||||
Amarin Corporation | 351 | 2023q2 | |||||||||
Anika Therapeutics | 309 | 2023q3 | |||||||||
ANI Pharmaceuticals | 1,261 | 2023q3 | |||||||||
AstraZeneca | 116,221 | 2024q1 | |||||||||
Aurinia Pharmaceuticals | 958 | 2021 | |||||||||
Aurora Cannabis | 1,021 | 2022q2 | |||||||||
Axsome Therapeutics | 3,872 | 2024q2 | |||||||||
Aytu BioPharma | 10 | 2022 | |||||||||
Bausch Health | 3,175 | 2023 | |||||||||
Bayer | 28,862 | 2022 | |||||||||
Beyond Air | 50 | 2024q1 | |||||||||
Bolt Biotherapeutics | 46 | 2023q3 | |||||||||
Bristol-Myers Squibb | 107,781 | 2023q3 | |||||||||
Canopy Growth | 702 | 2024q3 | |||||||||
CanSino Biologics | 530 | 2024q1 | |||||||||
Cipla | 13,230 | 2022 | |||||||||
Citius Pharmaceuticals | 65 | 2023q3 | |||||||||
Compass Pathways | 312 | 2023q3 | |||||||||
Compugen | 164 | 2021 |